Search Results

240 results for orex

16 Biotechnology Stocks to Sell Now

By Portfolio Grader

This week, the overall grades of 16 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or…

Rate Cut Central: 3 Stocks to Buy for Massive Gains Thanks to the Fed

By Matthew Farley, InvestorPlace Contributor

Unlock massive gains with these three stocks to buy as the Fed cuts rates. Discover undervalued opportunities.

3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck

By Josh Enomoto, InvestorPlace Contributor

Sears, Angie’s List Spike — Thursday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger

Sears Holdings and Angie’s List both posted quarterly losses Thursday, but other positive news sent their shares higher.

REIT ProLogis (PLD) Opens Lease on New High

By Deborah OMalley, InvestorPlace Writer

9 Best Cheap Stocks to Buy for 2015

By Jeff Reeves

If you’re looking for the best cheap stocks to buy, you can’t just rummage in the bargain bin. You have to find stocks that either…

Investors Bid Up Homebuilders, Energy Stocks — Monday’s IP Market Recap

By Kyle Woodley, Senior Investing Editor, Kiplinger

A rise in pending home sales lifts equities to a flat day overall. Lowe’s joins the homebuilders’ rise for the day.

11 Cheap Stocks to Buy Under $10

By Jeff Reeves

If you do the research and look at fundamentals first, you can find cheap stocks to buy that are more than just a crap shoot.

The Sad Skinny On Obesity-Drug Stocks

By Barry Cohen, Health Care Writer

Obesity drugs have yet to produce a big payday.

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

By Barry Cohen, Health Care Writer

Vivus and Orexigen’s diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.

One Gigantic Reason Inflation Should Crash Into Summer

By Luke Lango, InvestorPlace Senior Investment Analyst

We believe the biggest reason inflation is going to crash this summer is shockingly simple: The U.S. consumer is done paying up for stuff.

Bet on a Bounce with These Biotech ETFs

By Todd Shriber, InvestorPlace Contributor

Biotech stocks may have taken a beating lately, but that may just make these biotech ETFs more of a bargain.

5 Ebola Stocks – Invest in Preventing a U.S. Ebola Outbreak

By Jeff Reeves

Ebola stocks are in the news thanks to fears of a U.S. outbreak. So which Ebola stock investments are safe, and which are big risks?

3 Huge Healthcare Trends Can Fatten Your Portfolio

By Traders Reserve

Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities

Arena Pharmaceuticals (ARNA) Stock Crippled By Risk, Dilution

By John Divine, InvestorPlace Assistant Editor

Arena Pharmaceuticals (ARNA) stock is up 35% this year, but its prospects are crippled by risks as a recent secondary offering raises eyebrows.

Why Now Is the Time to Pile Back Into Biotech Stocks (IBB, XBI)

By John Divine, InvestorPlace Assistant Editor

For years, biotech stocks have outperformed the market. In light of their recent downturn, now’s a fine time to buy biotech ETFs like IBB and…

Vivus, Inc. (VVUS): Earnings Preview

By James Brumley, InvestorPlace Feature Writer

The VIVUS earnings report coming on Monday could be a harsh reality check about the long-term prospects for Qsymia.

Don’t Buy Orexigen on Diet Pill Hopes

By James Brumley, InvestorPlace Feature Writer

Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that’s brought nothing but disappointment to investors: weight-loss drugs.

3 Deeply Undervalued Dividend Stocks to Buy for High Total Returns in Q2

By Faisal Humayun, InvestorPlace Contributor

These are the undervalued dividend stocks to buy before they trend higher on the back of positive financial metrics.

3 Hidden Penny Stocks Ready to Explode Next Month

By Yiannis Zourmpanos, InvestorPlace Contributor

Discover the penny stocks to buy with leads in resource expansion, user engagement and cash and crypto assets.

Hide Out from Volatility in … Biotech?

By Rick Rouse, Editor, Momentum Options

On April 19, Zafgen sold six million shares, one million more than initially planned.

Is Arena Pharmaceuticals Any More Attractive Now That the Dust Is Settling?

By James Brumley, InvestorPlace Feature Writer

Now that the Belviq approval-fueled craze has waned, investors can take a clearer look at Arena’s numbers. They might be pleasantly surprised.

Obesity: The Next Investment Driver

By James Brumley, InvestorPlace Feature Writer

The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to…

7 Long-Term Demographic Trends to Play

By Alyssa Oursler, InvestorPlace Contributor

Earnings and stock fundamentals are important, but don’t miss the forest while looking at the trees. Here are the big-picture demographic trends to keep your…

5 – 10 of 240 results